Ctrl

K

Eluxadoline

Class
Antidiarrheal agents
Subclass
Opioid receptor modulators
Substance name
Eluxadoline
Brand names
Viberzi®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Treatment of IBS
•
100 mg PO BID
Indications for use
Labeled indications
Adults
•
Treatment of IBS
Safety risks
Contraindications
A history of pancreatitis, known or suspected pancreatic duct obstruction, or alcoholism
A hypersensitivity to eluxadoline
Chronic or severe constipation or gastrointestinal obstruction
Warnings and precautions
Drug abuse
•
Use caution with a history of substance abuse.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
•
Use acceptable. No dose adjustment required.
Hepatic impairment
Child-Pugh A (mild)
•
Reduce dose. Start at dose of 75 mg PO BID. Monitor for toxicity.
Child-Pugh B (moderate)
•
Reduce dose. Start at dose of 75 mg PO BID. Monitor for toxicity.
Child-Pugh C (severe)
•
Do not use.
Substantial chronic alcohol consumption
•
Do not use.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Use only if benefits outweigh potential risks.
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
Bronchospasm, cognitive impairment, gastroesophageal reflux, pharyngitis, abdominal pain, constipation, dizziness, euphoria, fatigue, flatulence, nausea, skin rash, somnolence, vomiting, wheezing
Uncommon < 1%
•
Acute pancreatitis
Unknown frequency
•
Angioedema, gastrointestinal perforation, ↑ liver enzymes, maculopapular rash, chest pain, dyspnea, itching, respiratory depression
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource